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introduction Quality in medicine is defined as the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and the degree to which they are consistent with current professional knowledge [1] . Based on national and regional registries in Denmark, Switzerland, England, Germany, and the Netherlands, the European experience has been that <50% of patients are treated according to protocols and/or benefit from the minimum required surgery for ovarian cancer, let alone complete cytoreductive surgery [2] . Of the 40 patients referred to a German tertiary centre after primary surgery, only 5 were considered to have received standard management [3] . Even among teams participating in randomized, controlled trials from centres treating more than 20 patients per year, adequate staging for early-stage ovarian cancer occurred in not more than 37%. This was significantly different when compared with centres treating less than five patients per year, where the rate of complete staging was merely 21% [4] . The mere implementation of a quality management programme impacts survival [5, 6] . Our objective was to define quality indicators for the initial management of patients with ovarian cancer.
materials and methods
The methodology for the definition of quality indicators relevant to assessing the performance and outcome of care is available [7] . Indicators serve as measurement tools to monitor, assess, and ultimately improve quality of care. They give practitioners and health administrators a quantitative basis for improving care and organizational processes. They also facilitate the documentation of quality of care, the comparison of performance structures, and the establishment of organizational priorities as a basis for accreditation.
The indicators are based on the standards of practice determined from scientific evidence or expert consensus. The key characteristics of an ideal indicator are clear definition, sensitivity and specificity, clinical relevance, the ability to generate comparisons, and a scientific basis.
A literature search limited to publications in French and English was conducted for each indicator according to the following strategy. A query using the Medline® (OVID interface) database was carried out using search equations for the period between January 2000 and August 2011 (see supplementary appendix 1, available at Annals of Oncology online) (with the exception of two equations for which no search period was determined due to a lack of data retrieved when applying the limit of the time period).
After management of duplicates, this search strategy identified 307 references. When consecutive publications were identified, only the last publication describing the largest number of patients was chosen.
The indicators were divided into structural indicators, process indicators, and outcome indicators [7] . Structural indicators correspond to healthcare facility resources, including material (equipment), human (number and qualification of staff ), and organizational resources. Process indicators explore the means implemented to achieve an optimal result. Outcome indicators describe the objectives of the treatment-or a surrogate outcome, the impact of the treatment on quality of life, and the risk-benefit balance. Considering the multidisciplinary nature of ovarian cancer management, criteria related to medical oncology environment were included.
The final outcome criterion, such as cancer survival, may have to be replaced by a surrogate outcome that can be assessed in a timely fashion. The surrogate indicator must be predictive of the final outcome. Once an indicator has been determined to be directly related to the final result, it then becomes an indirect measure of it. For example, complete cytoreduction in advanced-stage ovarian cancer is an indirect measure of the chances of survival.
Quality of evidence was rated as moderate when based on expert consensus. The indicators will be presented as indicated in Table 1 and rated as indicated in Table 2 [8, 9] and literature data [10] . The relationship between undergoing visceral surgery and survival has been demonstrated [10] . Visceral surgery is necessary in over 50% of patients to achieve complete cytoreduction [11] . Quantitative indicators by surgeon [12] [13] [14] [15] and by institution [12] [13] [14] [16] [17] [18] [19] [20] [21] were derived from the most compelling literature data (see discussion section).
Indicator 1.2: Formalized collaboration of the surgical team with a medical oncologist
Field of application: No restriction Table 2 . Presentation of confidence/impact rating The importance of standardization to achieve improved completeness, reproducibility, and evaluation of data pertaining to peritoneal extension and residual tumour has been documented in several studies [32] [33] [34] [35] . The prognostic value of the presence and extent of peritoneal carcinomatosis is documented [36] [37] [38] . The scores evaluating the extension of carcinomatosis were ranked at a consensus conference [39] . The Sugarbaker CC-score is the most widely used [40] . of pathological reports for ovarian cancer found that the origin of the tumour was missing in 20.5% of reports and the histological grade was absent in 10% [43] . This advocates for the use of templates based on data from the literature [44] [45] [46] outcome indicators overall survival of patients with cancer of the ovary stage III-IV was proportional to the proportion of optimal debulking surgery [47] . An analysis of a single-centre prospective cohort showed the direct impact of the increase in the proportion of patients with complete surgical resection improved overall survival [48] . Analysis of multicentre prospective cohorts from three randomized trials showed that the median overall survival of patients with ovarian cancer stage IIB-III-IV reached 99 months in cases where complete surgical resection was achieved [49] . A recent meta-analysis by the Cochrane group revealed that when compared with microscopic residual disease, the risk of death is two times greater if there is residual disease <1 cm and three times higher in cases where residual disease measures >1 cm [50] . This concept is valid regardless of the timing of surgery and applies to the policy of neoadjuvant chemotherapy, which is not a substitute for complete resection [51] . The 70% target in advanced ovarian cancers has been reached in the most recent report on day-to-day practice of French centres in a multicentre study in the current era of complete cytoreductive surgery [11] . [11] . The Society of Surgical Oncology (USA) and the European Society of Gynaecological Oncology [8, 9] took a position to promote the training of gynaecological surgeons treating cancer for abdominal procedures including colorectal resection and diaphragm stripping and resection [9] . Surgeons who perform radical surgery in more than 50% of stage IIIc ovarian cancer cases obtain a median survival of 5.9 years compared with 2.5 years for other surgeons [10] . The rate of visceral surgery necessary to achieve complete cytoreduction (see test results) has been confirmed to be more than 50% of cases [11] . The technical ability of the surgeon must be adapted to this context.
The experience and caseload required are diversely estimated. In a systematic review, DuBois et al. [12] were unable to recognize the number of operations per surgeon as prognostic. In a US study based on the population of Maryland, surgeon volume significantly and independently decreased the risk of postoperative mortality by 69%, despite achieving a greater number of cytoreductive surgeries. The threshold was set at 10 cases per year per surgeon [14] .
However, the review by DuBois [12] did not take into account the following two publications that gave evidence of a relationship between quality and volume [13, 18] . Finally, other publications after the DuBois systematic review complete the documentation. A US population-based study from Maryland assessing the influence of the number of procedures per institution (threshold of 20 cases per year) found an increase in the rate of cytoreduction (44%) with a paradoxical decrease in the duration of hospitalization, and as a result, a reduction in hospital costs [14] . In an Austrian study, a number of 24 per year established in a previous publication of the same investigators was confirmed as being prognostic [hazard ratio 1.38, confidence interval (CI) 1.2-1.7, P < 0.001] in a multivariate analysis [20] . A US-based study centred on the National Cancer Database for stage IIIc/IV between 1996 and 2005 included 45 929 patients. Survival was correlated with institutional volume. Compared with the reference point '1', which represents institutions with more than 35 cases per year, the relative risk is 1.08 (significant) for institutions in the 9-20 case-per-year bracket, and 1.14 (significant) for those seeing less than nine cases per year. These differences persisted after accounting for treatment modalities. Considering the most recent evidence, the threshold was thus set at 20 interventions per year [21] . A Norwegian study also shows that the threshold of 10 surgeries per year per surgeon is prognostic [15] . An indirect argument was presented through the analysis of treatment results for women with ovarian cancer in East Anglia between 1996 and 2003 (3406 patients) [55] . A multidisciplinary approach and centralization of treatment were accompanied by improved prognosis in this population (hazard ratio 0.71, CI 0.64-0.79).
Quality of surgical care as a component of a comprehensive regimen of multidisciplinary management has been shown to benefit the patient in many types of malignancies. Implementation of a quality improvement programme helped to reduce both morbidity and costs in other tumours where surgical intervention is also high risk [56] . Structured operative reports are associated with a quality assurance programme [33, 34] . There is a consensus that multidisciplinary approach in cancer care benefits the patient [57, 58] .
Careful perioperative management and collaboration with the anaesthetic team is critical. The dire prognosis of ovarian cancer, a condition that is not amenable to current screening techniques and generally presents at an advanced stage, justifies specific measures to improve oncological outcomes while preventing an increase in the complication rate of aggressive surgical management. Among the necessary actions, a quality assurance programme is obviously required for surgery, as there is evidence that most ovarian cancer surgeries in non-specialized centres are suboptimal due to lack of skill and training in visceral surgery and lack of awareness of the need for complete cytoreduction. There is also evidence that the reduction in mortality from complex procedures is more related to the ability to manage complications than to surgical volume [59] .
A multidisciplinary group representing the full range of learned societies in a single European country came to a consensus on defining structural, process, and outcome indicators supported by solid bibliographic evidence to assess the quality of surgical management of ovarian cancer. The enforcement of a quality assurance programme using these indicators in France, or their adaptation to practice in any country, would undoubtedly promote improvement in the quality of care for ovarian cancer patients and would result in a dramatic positive impact on their survival. The costeffectiveness ratio of this policy has been shown to be favourable in experienced compared with less experienced centres. In spite of an obvious need for specific resources and an increase in short-term operational costs, such a policy is then not only beneficial to the patient, but is also profitable for the healthcare system [52, 54, 60] .
